白芍总苷治疗系统性红斑狼疮的临床研究

作者	单位
张洪峰	中国医科大学附属第一医院风湿免疫科
肖卫国	中国医科大学附属第一医院风湿免疫科
侯平	中国医科大学附属第一医院风湿免疫科

摘要点击次数: 1345

全文下载次数: 3

中文摘要:

目的研究白芍总苷(TGP)对系统性红斑狼疮(SLE)治疗作用及不良反应。方法分析29例连续服用TGP5年以上的SLE患者(TGP1组)及47例连续或间断服用TGP1～5年的SLE患者(TGP2组)的临床资料。选择年龄、患病时间、尿蛋白及SLE活动性指数(SLEDAI)与TGP1组及TGP2组匹配的SLE患者20例作为对照组。比较TGP1组、TGP2组及对照组治疗5年后3组间的日平均泼尼松用量、环磷酰胺(CTX)总量、尿蛋白、SLEDAI评分、复发例数及感染事件。结果 TGP1组日平均泼尼松用量、CTX总量及SLEDAI评分明显小于对照组(P<0.01);日平均泼尼松用量、CTX总量及SLEDAI评分明显小于TGP2组,差异有统计学意义(P<0.05,P<0.01)。TGP2组日平均泼尼松用量和CTX总量与对照组比较,也明显减少(P<0.05)。3组间尿蛋白比较差异无统计学意义。5年中复发情况,TGP1组有1例,TGP2组有9例,对照组有7例。5年中TGP1组发生感染事件3例,GTP2组17例,对照组18例。3组间均未发现与TGP相关的不良反应。结论 TGP治疗SLE有确切的治疗效果,可减少日平均泼尼松用量及CTX总量,减少复发例数及感染事件的发生,尤其是连续服用5年以上。

英文摘要:

Objective To study the therapeutic efficacy and adverse reaction of total glucosides of paeony(TGP,extracted from Paeonia lactiflora Pall.) in patients with systemic lupus erythematosus(SLE).MethodsClinical data of patients with SLE were analyzed.Those who orally took TGP continuously for five years or more were taken as TGP1 group(29 cases).Those who orally took TGP continuously or intermittently for more than one year but less than five years were taken as TGP2 group(47 cases).Twenty patients matched with the TGP1 group and the TGP2 group in age,affected duration,urine protein,and SLE disease activity index(SLEDAI) were selected as the control group.The average daily dose of prednisone,total cyclophosphamide(CTX) dose,urine protein,SLEDAI score,recurrent case,and episodes of infection were compared among the three groups after five-year treatment.Results The average daily dose of prednisone,total CTX dose,and SLEDAI score were obviously lower in the TGP1 group than in the control group(P<0.01).The average daily dose of prednisone,total CTX dose,and SLEDAI score were obviously lower in the TGP1 group than in the TGP2 group,Significant difference was shown(P<0.05).The average daily dose of prednisone and total CTX dose were lower in the TGP2 group than in the control group(P<0.05,P<0.01).There was no statistical difference in the urine protein among the three groups.As for the recurrence,one case occurred in the TGP1 group,nine in the TGP2 group,and seven in the control group.As for episodes of infection,there were three cases in the TGP1 group,seventeen in the TGP2 group,and eighteen in the control group during the five years.No adverse reaction correlated to TGP was found in the three groups.Conclusions TGP had definite therapeutic efficacy in treatment of patients with SLE.It could reduce the average daily dose of prednisone and the total CTX dose,lower the recurrent cases and episodes of infection,especially for the medication of more than five years.

关闭